What dose of enoxaparin should be administered and for how many days?

Enoxaparin Dosing for Acute Coronary Syndromes

For ACS patients, administer enoxaparin 1 mg/kg subcutaneously every 12 hours as initial therapy, continuing until revascularization or for the duration of hospitalization up to 8 days. 1, 2, 1

Standard Dosing Algorithm

Initial Therapy (Medical Management)

• Standard dose: 1 mg/kg subcutaneous every 12 hours 1, 2, 1
• Duration: Continue until revascularization or up to 8 days of hospitalization 1, 2, 1

With Fibrinolytic Therapy

The dosing differs based on age:

For patients <75 years old:

• 30 mg IV bolus initially
• Followed in 15 minutes by 1 mg/kg subcutaneous every 12 hours
• Maximum 100 mg for the first 2 doses 1, 2, 1, 3

For patients ≥75 years old:

• No IV bolus
• 0.75 mg/kg subcutaneous every 12 hours
• Maximum 75 mg for the first 2 doses 1, 2, 1, 3

Renal Dosing Adjustments

Critical adjustment: If creatinine clearance <30 mL/min (regardless of age):

• Reduce to 1 mg/kg subcutaneous once daily (every 24 hours) 1, 2, 1, 3

This represents the most recent 2025 ACC/AHA/ACEP/NAEMSP/SCAI guidelines, which supersede the 2015 and earlier recommendations.

Duration of Therapy

Minimum duration: 48 hours 3

Optimal duration: Continue for the entire hospitalization, up to 8 days, or until revascularization is performed 1, 2, 1, 3

The guidelines emphasize that anticoagulation should be maintained until the patient undergoes revascularization to reduce ischemic complications 2.

PCI-Specific Dosing Adjustments

If the patient proceeds to PCI while on enoxaparin:

Timing-based supplementation:

• If last subcutaneous dose was within 8 hours: Give no additional enoxaparin 1, 2, 1
• If last dose was 8-12 hours earlier OR only 1 dose given: Give 0.3 mg IV 1, 2, 1
• If no prior enoxaparin: Give 0.5-0.75 mg/kg IV bolus 1, 2, 1

Critical Pitfalls to Avoid

Do not switch between anticoagulants: Patients initially treated with enoxaparin should not be switched to UFH and vice versa due to increased bleeding risk 4. This is a Class III (Harm) recommendation.

Elderly patients: The elimination of the IV bolus in patients ≥75 years receiving fibrinolysis is crucial—this modification reduces bleeding risk while maintaining efficacy 1, 2, 1, 3.

Renal impairment: The once-daily dosing for CrCl <30 mL/min is essential to prevent drug accumulation and bleeding complications 5. Enoxaparin undergoes significant renal clearance, with clearance reduced by 44% in severe renal impairment 5.

Evidence Quality

These recommendations are based on the 2025 ACC/AHA/ACEP/NAEMSP/SCAI guidelines published in both Journal of the American College of Cardiology and Circulation 1, 2, 1, representing the highest quality and most current evidence available. The enoxaparin regimen carries a Class I (strong) or Class IIa recommendation with Level of Evidence A in most ACS contexts 4, 3.

The 2025 guidelines note that while enoxaparin may be considered as an alternative to UFH at the time of PCI (Class IIb, Level B-R), it remains a reasonable choice for initial anticoagulation therapy in both STEMI and NSTE-ACS with established efficacy 1, 2.